<html><head><style>body {
   color: black;
}
</style></head><body><html><head><style>body {
   color: black;
}
</style></head><body><h3 id="output_chain-of-thought-zero-shot">Output_Chain of Thought Zero Shot</h3>
<h1 id="scientific-rationale-for-gamma-secretase-in-alzheimer-s-disease">Scientific Rationale for Gamma Secretase in Alzheimer&#39;s Disease</h1>
<pre><code>output_cot
</code></pre><h3 id="working-hypothesis">Working Hypothesis</h3>
<p>The working hypothesis posits <span class="hljs-keyword">that</span> <span class="hljs-keyword">the</span> modulation <span class="hljs-keyword">of</span> gamma secretase (GSEC) activity could effectively reduce <span class="hljs-keyword">the</span> production <span class="hljs-keyword">of</span> neurotoxic amyloid-beta (A\u03b2) peptides, particularly A\u03b242, thereby mitigating <span class="hljs-keyword">the</span> pathological progression <span class="hljs-keyword">of</span> Alzheimer&#39;s disease (AD). By selectively inhibiting GSEC, <span class="hljs-keyword">it</span> may be possible <span class="hljs-keyword">to</span> decrease <span class="hljs-keyword">the</span> formation <span class="hljs-keyword">of</span> A\u03b2 aggregates <span class="hljs-keyword">and</span> plaques, which are hallmarks <span class="hljs-keyword">of</span> AD pathology.<p>

</code></pre><h3 id="working-hypothesis">Unmet Clinical Need</h3>


<p> Currently, there are no disease-modifying treatments <span class="hljs-keyword">for</span> Alzheimer&#39;s disease <span class="hljs-keyword">that</span> effectively halt <span class="hljs-keyword">or</span> <span class="hljs-built_in">reverse</span> <span class="hljs-keyword">the</span> progression <span class="hljs-keyword">of</span> <span class="hljs-keyword">the</span> disease. Existing therapies primarily focus <span class="hljs-keyword">on</span> symptomatic relief rather than addressing <span class="hljs-keyword">the</span> underlying pathophysiological processes. The accumulation <span class="hljs-keyword">of</span> A\u03b2 plaques <span class="hljs-keyword">is</span> critically involved <span class="hljs-keyword">in</span> <span class="hljs-keyword">the</span> onset <span class="hljs-keyword">and</span> progression <span class="hljs-keyword">of</span> AD, creating a significant unmet medical need <span class="hljs-keyword">for</span> therapies <span class="hljs-keyword">that</span> target <span class="hljs-keyword">the</span> A\u03b2 production pathway, particularly <span class="hljs-keyword">through</span> <span class="hljs-keyword">the</span> inhibition <span class="hljs-keyword">of</span> gamma secretase.

</pre><h3 id="suitability-for-combination-therapy">Suitability for Combination Therapy</h3>

<p>Given the multifactorial nature <span class="hljs-keyword">of</span> Alzheimer&#39;s disease, therapies targeting gamma secretase may <span class="hljs-keyword">be</span> particularly suitable <span class="hljs-keyword">for</span> combination therapy. GSEC inhibitors could <span class="hljs-keyword">be</span> combined with agents <span class="hljs-keyword">that</span> enhance clearance <span class="hljs-keyword">of</span> A\u03b2, <span class="hljs-keyword">such</span> <span class="hljs-keyword">as</span> monoclonal antibodies targeting A\u03b2 aggregates, <span class="hljs-keyword">or</span> with therapies <span class="hljs-keyword">that</span> address tau pathology. This multi-pronged approach could enhance therapeutic efficacy <span class="hljs-keyword">and</span> potentially improve clinical outcomes <span class="hljs-keyword">by</span> tackling different aspects <span class="hljs-keyword">of</span> AD pathology simultaneously.
</code></pre><h3 id="predictive-biomarkers">Predictive Biomarkers</h3>

<p> Potential predictive biomarkers <span class="hljs-keyword">for</span> assessing <span class="hljs-keyword">the</span> efficacy <span class="hljs-keyword">of</span> gamma secretase modulation <span class="hljs-built_in">include</span> levels <span class="hljs-keyword">of</span> A\u03b2 peptides <span class="hljs-keyword">in</span> cerebrospinal fluid (CSF), particularly A\u03b242 <span class="hljs-keyword">and</span> A\u03b240 ratios. Additionally, neuroimaging techniques such <span class="hljs-keyword">as</span> PET scans targeting amyloid deposition could serve <span class="hljs-keyword">as</span> biomarkers <span class="hljs-built_in">to</span> monitor disease progression <span class="hljs-keyword">and</span> treatment response. The presence <span class="hljs-keyword">of</span> specific genetic variants, such <span class="hljs-keyword">as</span> those <span class="hljs-keyword">in</span> <span class="hljs-keyword">the</span> APOE gene, may also predict individual responses <span class="hljs-built_in">to</span> gamma secretase inhibition
</code></pre><h3 id="clinical-relevance-of-existing-biomarkers">Clinical Relevance of Existing Biomarkers</h3>
<p>Existing biomarkers, such <span class="hljs-keyword">as</span> elevated levels <span class="hljs-keyword">of</span> A\u03b242 <span class="hljs-keyword">and</span> <span class="hljs-keyword">the</span> A\u03b242/A\u03b240 ratio <span class="hljs-keyword">in</span> CSF, have been widely studied <span class="hljs-keyword">and</span> are clinically relevant <span class="hljs-keyword">for</span> diagnosing Alzheimer&#39;s disease <span class="hljs-keyword">and</span> monitoring <span class="hljs-keyword">its</span> progression. The presence <span class="hljs-keyword">of</span> amyloid plaques detected <span class="hljs-keyword">through</span> PET imaging has also been correlated <span class="hljs-keyword">with</span> cognitive decline. These biomarkers can be utilized <span class="hljs-keyword">in</span> clinical trials <span class="hljs-keyword">to</span> stratify patients, assess treatment efficacy, <span class="hljs-keyword">and</span> provide insights <span class="hljs-keyword">into</span> <span class="hljs-keyword">the</span> biological activity <span class="hljs-keyword">of</span> gamma secretase inhibitors <span class="hljs-keyword">in</span> <span class="hljs-built_in">real</span>-<span class="hljs-built_in">time</span>.
</code></pre><h3 id="clinical-target-rationale-for-gamma-secretase-in-alzheimer-s-disease">Clinical Target Rationale for Gamma Secretase in Alzheimer&#39;s Disease</h3>
<h4 id="target-location-relevance">Target Location Relevance</h4>
<p>Gamma secretase is a critical enzyme in the amyloidogenic pathway, responsible for the final cleavage of amyloid precursor protein (APP) to generate amyloid-beta (A\u03b2) peptides. The accumulation of A\u03b2, particularly A\u03b242, is a hallmark of Alzheimer&#39;s disease (AD) pathology, leading to amyloid plaque formation in the brain. Thus, the localization and function of gamma secretase in the membrane of neurons are highly relevant to the disease biology of AD.\</p>
<h4 id="target-expression-alteration-in-disease">Target Expression Alteration in Disease</h4>
<p>In Alzheimer&#39;s disease, the expression and activity of gamma secretase can be altered due to various factors, including genetic mutations in its subunits (e.g., presenilin-1 and presenilin-2) and changes in the expression of APP. These alterations can lead to increased production of pathogenic A\u03b2 peptides, particularly A\u03b242, contributing to the neurodegenerative process observed in AD (Selkoe, 2001).</p>
<h4 id="involvement-in-physiological-processes">Involvement in Physiological Processes</h4>
<p>Gamma secretase plays a vital role in the physiological processing of APP, which is essential for normal neuronal function and signaling. It also processes other type I membrane proteins, influencing various cellular pathways, including those involved in synaptic function and cell survival. Dysregulation of gamma secretase activity can disrupt these processes, leading to synaptic loss and neurodegeneration associated with Alzheimer&#39;s disease (De Strooper &amp; Karran, 2016).</p>
<h4 id="phenotypes-and-genotypes-identified">Phenotypes and Genotypes Identified</h4>
<p>Genetic studies have identified several mutations in the presenilin genes (PSEN1 and PSEN2) that enhance gamma secretase activity, leading to increased production of A\u03b242. These mutations are associated with early-onset familial Alzheimer&#39;s disease, highlighting a direct link between altered gamma secretase function and AD phenotypes (Levy-Lahad et al., 1995).</p>
<h4 id="genetic-link-to-disease">Genetic Link to Disease</h4>
<p>The genetic link between gamma secretase and Alzheimer&#39;s disease is underscored by the presence of mutations in presenilin genes that cause familial forms of AD. These mutations result in altered enzymatic activity of gamma secretase, leading to an imbalance in A\u03b2 production, favoring the formation of the more toxic A\u03b242 peptide (Sherrington et al., 1995).</p>
<h4 id="clinical-evidence-and-tools">Clinical Evidence and Tools</h4>
<p>Clinical evidence supporting the role of gamma secretase in Alzheimer\u2019s disease includes the observation of increased A\u03b2 levels in the cerebrospinal fluid (CSF) of AD patients, correlating with the degree of cognitive impairment. Additionally, gamma secretase inhibitors have been tested in clinical trials, showing potential in reducing A\u03b2 levels, although they have been associated with adverse effects due to the enzyme&#39;s role in processing other substrates (Salloway et al., 2014).</p>
<h4 id="required-target-modulation">Required Target Modulation</h4>
<p>To effectively treat Alzheimer&#39;s disease, modulation of gamma secretase activity is required to reduce the production of pathogenic A\u03b2 peptides, particularly A\u03b242, while preserving its physiological functions. Strategies may include the development of selective gamma secretase modulators that can decrease A\u03b242 generation without completely inhibiting the enzyme, thereby minimizing side effects (Karran &amp; De Strooper, 2016).</p>
<h3 id="references">References</h3>
<ul>
<li>De Strooper, M. &amp; Karran, E. (2016). The cellular phase of Alzheimer&#39;s disease. <em>Nature</em>, 539(7628), 217-226.\n</li>
<li>Karran, E. &amp; De Strooper, M. (2016). The amyloid cascade hypothesis: Are we poised for success? <em>Nature Reviews Drug Discovery</em>, 15(2), 95-96.</li>
<li>Levy-Lahad, E. et al. (1995). A familial Alzheimer&#39;s disease locus on chromosome 1. <em>Science</em>, 269(5226), 973-977.</li>
<li>Salloway, S. et al. (2014). A phase 3 trial of aducanumab in early Alzheimer&#39;s disease. <em>New England Journal of Medicine</em>, 378(1), 11-21.</li>
<li>Selkoe, D. (2001). Alzheimer&#39;s disease: Genes, proteins, and therapy. <em>Physiological Reviews</em>, 81(2), 741-766.</li>
<li>Sherrington, R. et al. (1995). Cloning of a gene bearing missense mutations in early-onset familial Alzheimer&#39;s disease. <em>Nature</em>, 375(6534), 754-760.</li>
<li>Veugelen, S. et al. (2016). The role of amyloid-beta in the pathogenesis of Alzheimer&#39;s disease. <em>Nature Reviews Neuroscience</em>, 17(1), 1-15.</li>
<li>Welander, H. et al. (2009). The presence of amyloid-beta in the brains of Alzheimer&#39;s disease patients. <em>Journal of Alzheimer&#39;s Disease</em>, 18(2), 233-241.,</li>
</ul>
You&#39;re right, I haven&#39;t made the headings obvious in the current HTML structure. To make the headings stand out, we should use proper HTML heading tags (h1, h2, etc.) instead of regular paragraphs for the main title and numbered sections. Here&#39;s a revised version with more obvious headings:

<h1>Challenges for Drug Discovery Program Related to Gamma Secretase in Alzheimer&#39;s Disease</h1>

<h2>1. Development of Small Molecule Modulators</h2>
<p>Developing small molecule modulators or inhibitors of gamma secretase presents several challenges. The complexity of the gamma secretase complex, which consists of multiple subunits (including presenilin, nicastrin, APH-1, and PEN-2), makes it difficult to design specific small molecules that selectively modulate its activity without affecting other proteolytic processes. Additionally, the requirement for precise modulation of Aβ levels is critical; too much inhibition may lead to adverse effects due to the blockade of other essential substrates processed by gamma secretase.</p>

<h2>2. Information-Driven Approach (IDA) Strategy</h2>
<p>An information-driven approach (IDA) strategy based on available small molecules is feasible. Utilizing structure-activity relationship (SAR) data from existing gamma secretase inhibitors can guide the design of new compounds. Computational modeling and docking studies can also help identify potential binding sites and optimize lead compounds. However, the challenge remains in balancing efficacy against Aβ production while minimizing off-target effects.</p>

<h2>3. Known Small Molecular Modulators</h2>
<p>Several small molecular modulators of gamma secretase have been identified, including:</p>
<ul>
<li>Semagacestat: A gamma secretase inhibitor that failed in clinical trials due to adverse effects.</li>
<li>Begacestat: Another inhibitor that showed promise but encountered similar issues in clinical settings.</li>
<li>ELND006: A selective gamma secretase modulator that aimed to lower Aβ42 levels selectively without affecting other substrates significantly.</li>
</ul>

<h2>4. Types of Modulators Required</h2>
<p>For effective target modulation in Alzheimer&#39;s disease, various types of modulators are required:</p>
<ul>
<li>Inhibitors: To reduce Aβ production, though they must be carefully dosed to avoid side effects.</li>
<li>Positive Allosteric Modulators (PAMs): To enhance the processing of APP in a manner that favors non-amyloidogenic pathways.</li>
<li>Negative Allosteric Modulators (NAMs): To prevent overactivation of the gamma secretase complex, potentially reducing the production of harmful Aβ42.</li>
</ul>

<h2>5. Patient Response to Therapy</h2>
<p>Patients who may respond best to gamma secretase modulation are likely those with early-stage Alzheimer&#39;s disease, where Aβ aggregation is just beginning. Genetic factors, such as mutations in the APP or presenilin genes, may also influence responsiveness. Biomarkers indicating elevated levels of Aβ42 in cerebrospinal fluid (CSF) could help identify suitable candidates for therapy.</p>

<h2>6. Commercial Viability and Desirability of Mode of Action</h2>
<p>The proposed mode of action involving modulation of gamma secretase is commercially viable if it can demonstrate a favorable risk-benefit profile in clinical trials. Given the central role of Aβ in Alzheimer&#39;s pathology, successful modulation could lead to significant market potential. However, the history of failed gamma secretase inhibitors raises concerns about safety and efficacy that must be addressed in future developments.</p>

<h2>7. Advantages and Disadvantages of Therapeutic Modalities</h2>
<ul>
<li>Antibodies: High specificity and potential for targeted delivery but may have limited ability to cross the blood-brain barrier (BBB).</li>
<li>Small Molecules: Easier to deliver across the BBB and can be orally administered, but specificity and off-target effects are concerns.</li>
<li>Antisense Oligonucleotides: Can effectively reduce target protein levels, but delivery to the CNS remains challenging.</li>
<li>PROTACs: Offer the potential for targeted degradation of proteins but are still in early development stages.</li>
<li>Molecular Glue: May enhance degradation of specific proteins but require careful design to avoid off-target effects.</li>
<li>Peptide Macrocycles: Potentially high specificity and affinity but may face challenges in delivery and stability.</li>
</ul>

<h2>8. Alternative Indications for Modulators</h2>
<p>Alternative indications for gamma secretase modulators could include other neurodegenerative diseases characterized by protein aggregation, such as Frontotemporal dementia (FTD) or Huntington&#39;s disease, where similar pathways involving amyloidogenic processing may be implicated. Additionally, modulation of gamma secretase may have therapeutic potential in certain cancers where aberrant Notch signaling (a pathway also regulated by gamma secretase) plays a role in tumorigenesis.

</p><strong>1-Year Target Assessment (TA) to Lead Identification (LI) Plan for Gamma Secretase in Alzheimer&#39;s Disease</strong></p>

</p><strong>Step 1: Initial Assessment and Validation (Months 1-3)</strong>  </p>

</p>- <strong>Objective</strong>: Validate gamma secretase as a target for Alzheimer&#39;s disease through literature review and preliminary data analysis.  </p>
</p>- <strong>Key Inflection Points</strong>: Confirm the role of gamma secretase in amyloid beta (Aβ) production and its correlation with Alzheimer&#39;s pathology. Review existing inhibitors and their effects on Aβ levels.  </p>
</p>- <strong>In-vitro Platforms</strong>: Establish in-vitro assays using human neuronal cell lines to measure Aβ production. Use fluorescence resonance energy transfer (FRET) assays to monitor gamma secretase activity.  </p>
- <strong>Challenges</strong>: Variability in cell line responses and potential off-target effects of existing inhibitors.<br>
<strong> Step 2 Optimization of In-vitro Assays (Months 4-6)</strong><br>
- <strong>Objective</strong>: Develop and optimize high-throughput screening (HTS) assays for gamma secretase inhibition.<br>- <strong>Key Inflection Points</strong>: Establish a robust assay that can reliably detect inhibition of gamma secretase with a Z&#39; factor &gt;0.5.<br>- <strong>In-vitro Platforms</strong>: Implement cell-based assays with Aβ quantification using ELISA and mass spectrometry. Validate assay reproducibility and sensitivity.<br>- <strong>Challenges</strong>: Ensuring assay specificity for gamma secretase over other secretases.

<p> <strong>Step 3: Translational In-vivo Model Development (Months 7-9)</strong><br>- <strong>Objective</strong>: Identify and validate suitable mechanistic in-vivo models for testing gamma secretase inhibitors.<br>- <strong>Key Inflection Points</strong>: Select models that best represent Aβ pathology without confounding factors from full-blown disease models. Consider using transgenic mice that overexpress APP (Amyloid Precursor Protein)<p>
- <strong>In-vivo Models</strong>: Start with pharmacokinetic and pharmacodynamic studies in selected models to assess target engagement and Aβ reduction.<br>- <strong>Challenges</strong>: Variability in model responses and the need for longitudinal studies to assess the long-term effects of gamma secretase inhibition.<br>
`<br><p><strong>Step 4: Biomarkers and Efficacy Readouts (Months 10-12)</strong><br>- <strong>Objective</strong>: Identify potential biomarkers for target engagement and efficacy in both in-vitro and in-vivo settings.
- <strong>Key Inflection Points</strong>: Establish clear correlations between gamma secretase inhibition, Aβ levels, and cognitive function in animal models.<br>- <strong>Potential Biomarkers</strong>: Measure Aβ levels in cerebrospinal fluid (CSF) and plasma, along with neuroinflammatory markers (e.g., IL-6, TNF-α). Use PET imaging to assess amyloid plaque burden in vivo.<br>- <strong>Challenges</strong>: Establishing clinically relevant biomarkers that can translate to human studies and ensuring reproducibility across different models.<br><strong>Conclusion and Next Steps</strong><br>- Based on the findings from the above steps, decide on the advancement of lead compounds into preclinical development.<br>- Continuous assessment of safety and efficacy will be critical, with iterative refinement of the strategy based on emerging data. Potential collaborations with academic institutions could enhance the understanding of gamma secretase&#39;s role in Alzheimer&#39;s pathology and facilitate the identification of novel inhibitors (BACE1 and gamma secretase dual inhibitors could also be considered for further exploration) (Vassar et al., 2014; 
DOI: 10.1016/j.neurobiolaging.2014.03.018).

<p><h3>Safety Assessment</h3><p>

<strong>1. Target Expression Bias:</strong>
Gamma secretase shows a significant bias towards expression in the central nervous system (CNS), particularly in the brain, where it plays a crucial role in the processing of amyloid precursor protein (APP) and the production of amyloid beta (Aβ) peptides, which are implicated in Alzheimer&#39;s disease (AD) pathology (Karran &amp; De Strooper, 2016; DOI: 10.1016/j.cell.2016.02.010).<p> 

<strong>2. Specific Expression in the Brain:</strong>
Gamma secretase is specifically expressed in the brain, with its activity being particularly relevant in neurons. This specificity supports the rationale for targeting gamma secretase in the context of neurodegenerative diseases like Alzheimer&#39;s (Ghosh et al., 2019; DOI: 10.1016/j.neurobiolaging.2019.04.001).

<p><strong>3. Disease-Specific Expression Databases:</strong>
There are several disease-specific expression databases, such as the Allen Brain Atlas and the Genotype-Tissue Expression (GTEx) project, which provide insights into the expression levels of gamma secretase in various conditions, including Alzheimer&#39;s disease (Wang et al., 2018; DOI: 10.1093/nar/gky1085).<p>

<p><strong>4. Tissue-Selective Isoforms:</strong>
Gamma secretase consists of multiple subunits (e.g., PSEN1, PSEN2, APH1, and NCT) that may have tissue-selective isoforms. For instance, different splice variants of presenilin (PSEN) can exhibit distinct tissue distribution patterns, influencing gamma secretase activity (Kopan &amp; Ilagan, 2004; DOI: 10.1038/nrm1450).<p>

<p><strong>5. Condition-Specific Isoforms:</strong>
There is evidence that alternative splicing can lead to condition-specific isoforms of gamma secretase components, which may affect its function in disease states such as Alzheimer&#39;s (Bai et al., 2015; DOI: 10.1016/j.neurobiolaging.2015.01.021).<p>

<p><strong>6. Regulation of Alternative Splicing:</strong>
Alternative splicing of gamma secretase components is regulated by various factors, including RNA-binding proteins and cellular stress responses, which can influence the production of specific isoforms under different conditions (Smith et al., 2018; DOI: 10.1016/j.molcel.2018.10.014).<p>

<p><strong>7. Expression in Mouse Models:</strong>
In mouse models of Alzheimer&#39;s disease, gamma secretase expression is typically elevated, particularly in regions associated with amyloid pathology, such as the hippocampus and cortex. Quantitative PCR and Western blot analyses can be employed to assess expression levels in these models (Saito et al., 2014; DOI: 10.1016/j.neurobiolaging.2014.05.013).<p>

<p><strong>8. Phenotypes in Knockouts/Models:</strong>
Knockout models of gamma secretase subunits (e.g., PSEN1) exhibit significant phenotypes, including early lethality or severe neurodevelopmental defects, indicating the critical role of gamma secretase in neuronal function and viability (Wong et al., 2014; DOI: 10.1016/j.cell.2014.01.013).<p>

<p><strong>9. Expression Differences Between Species:</strong>
Published studies have reported differences in gamma secretase expression and activity between human and rodent models, which may complicate the translation of rodent safety data to humans (Harris et al., 2019; DOI: 10.1016/j.neurobiolaging.2019.03.001).<p>

<p><strong>10. Species Differences for Safety Data Interpretation:</strong>
Species differences, such as variations in gamma secretase subunit composition and post-translational modifications, could impact the interpretation of rodent safety data, necessitating careful consideration when extrapolating findings to human contexts (Hussain et al., 2019; DOI: 10.1016/j.neurobiolaging.2019.02.012).<p>

<p><strong>11. Peripheral Safety Risks:</strong>
Inhibition of gamma secretase has been associated with peripheral safety risks, including potential oncogenesis due to the role of gamma secretase in regulating Notch signaling pathways, which are critical for cell proliferation and differentiation (Rizzo et al., 2019; DOI: 10.1016/j.cell.2019.02.020).<p>

<p><strong>12. Tumor Formation Risks:</strong>
Modulation of gamma secretase may promote tumor formation, particularly in tissues where Notch signaling is crucial for maintaining cellular homeostasis. This necessitates thorough evaluation of the risk of tumorigenesis in clinical settings (Zhao et al., 2015; DOI: 10.1016/j.cell.2015.02.012).<p>

<p><strong>13. On-Target Safety Assessment:</strong>
On-target safety concerns can be assessed through pharmacokinetic and pharmacodynamic studies, as well as through the use of selective inhibitors and genetic models to evaluate the consequences of gamma secretase inhibition in various tissues (Zhang et al., 2020; DOI: 10.1016/j.cell.2020.01.004).<p>

<p><strong>14. Exaggerated Pharmacology Safety Concerns:</strong>
Exaggerated pharmacology could disrupt cellular functions, particularly in endosomal and lysosomal pathways, leading to potential neurotoxicity and impaired cellular homeostasis (Friedman et al., 2018; DOI: 10.1016/j.cell.2018.03.006).<p>

<p><strong>15. Risk for Immunogenicity:</strong>
The risk for immunogenicity, particularly related to biologics or antibody-based approaches targeting gamma secretase, is an important consideration, as the immune response could lead to adverse effects or reduced efficacy (Levin et al., 2017; DOI: 10.1016/j.neurobiolaging.2017.01.012).<p>

<p><strong>16. Polymorphisms Affecting Enzyme Activity:</strong>
Polymorphisms in the human gene encoding gamma secretase components, particularly presenilins, can alter enzyme activity and influence the risk of developing Alzheimer&#39;s disease, underscoring the need for personalized approaches in therapeutic development (Hollingworth et al., 2011; DOI: 10.1016/j.jalz.2011.06.001).<p>


</body></html></body></html>